Cargando…
Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
Prevention and treatment strategies for heart failure (HF) in diabetes have not been fully established, at least partly due to lack of recognition of a pathological link between the two and effective antidiabetic agents for HF. Recent cardiovascular (CV) outcomes trials demonstrated that treatment w...
Autores principales: | Tanaka, Atsushi, Node, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968589/ https://www.ncbi.nlm.nih.gov/pubmed/29801492 http://dx.doi.org/10.1186/s12933-018-0719-7 |
Ejemplares similares
-
Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
por: Tanaka, Atsushi, et al.
Publicado: (2020) -
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020) -
Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017) -
The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022) -
The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)